Argatroban was the very first antithrombin agent that was approved for clinical use. It represents a synthetic arginomimetic drug with multiple pharmacologic properties. Unlike other antithrombin drugs, argatroban is a reversible antithrombin agent. Furthermore, it modulates endothelial cell function and downregulates various inflammatory and thrombotic cytokines. Argatroban is an effective anticoagulant agent, which at equivalent anticoagulant levels (activated clotting time; ACT) produces a stronger anticoagulant effect in comparison to heparins and hirudins. At a comparable ACT (300 s), argatroban produces much stronger inhibition of thrombin generation as measured by F1.2 and thrombin-antithrombin complex generation. Argatroban does not generate any neutralizing or non-neutralizing antibodies and, therefore, it does not require any dosage adjustment during the course of therapy as other thrombin inhibitors require. The pharmacological profile of argatroban is unique as this antithrombin drug not only inhibits thrombogenesis but also modulates cellular functions. Because of its broad spectral actions, argatroban will have more expanded indications.

Keywords:
Antithrombin, Anticoagulant, Thrombosis, Reversible inhibitor
This content is only available via PDF.
© 2002 S. Karger AG, Basel
2003
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.